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The inﬂuenza virus replicates in the host cell nucleus, and the progeny viral ribonucleoprotein com-
plex (vRNP) is exported to the cytoplasm prior to maturation. NS2 has a nuclear export signal that
mediates the nuclear export of vRNP by the vRNP–M1–NS2 complex. We previously reported that
the heat shock cognate 70 (Hsc70) protein binds to M1 protein and mediates vRNP export. However,
the interactions among M1, NS2, and Hsc70 are poorly understood. In the present study, we demon-
strate that Hsc70 interacts with M1 more strongly than with NS2 and competes with NS2 for M1
binding, suggesting an important role of Hsc70 in the nuclear export of vRNP.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Inﬂuenza viruses are enveloped, negative-strand RNA viruses
with segmented genomes, which belong to the family
Orthomyxoviridae. Inﬂuenza pandemics or seasonal epidemics
cause signiﬁcant morbidity and mortality in humans and animals.
The inﬂuenza virus binds to sialic acids on the cell surface via
hemagglutinin (HA) and is incorporated into the cell via endocyto-
sis. The low pH within the endosome promotes the fusion of the
viral membrane and endosome, which is accompanied by struc-
tural changes in HA [1]. Moreover, the H+ inﬂux from the endo-
some into the virion is mediated by the M2 protein. As a result,
the viral ribonucleoprotein complex (vRNP) dissociates from M1
protein and releases into the cytoplasm. vRNP comprises viral
RNA; NP; and the viral RNA polymerases PA, PB1, and PB2; and
each vRNP protein contains a nuclear localization signal (NLS).Thus, the cellular nuclear import factor, importin alpha, binds to
NLS and imports vRNP into the nucleus via the nuclear pore com-
plex. Further, replication and early transcription from vRNP occur
in the nucleus, and the viral mRNAs are exported from the nucleus
[2]. The newly synthesized viral proteins, i.e., NP, PB1, PB2, and PA,
are imported into the nucleus via their NLS, and they form a com-
plex with the newly synthesized viral RNA to form progeny vRNP
[3]. The progeny vRNP is exported from the nucleus into the cyto-
plasm by the cellular nuclear export factor CRM1/exportin1-med-
iated pathway and then transported via microtubules to beneath
the cellular membrane [4,5], following which, virus assembly
occurs on the plasmamembrane with the newly synthesized struc-
tural proteins such as M1, M2, HA, neuraminidase (NA), and NS2.
The virus particles are then released from the cell via the activity
of NA [6].
The mechanism for the nuclear export of vRNP was initially
reported by Martin et al. [7]. M1 is essential for the nuclear export
of the progeny vRNP because the inhibition of M1 synthesis by
H-7 [8] and the microinjection of M1 antibody into infected
cells results in the inhibition of the nuclear export of vRNP.
CRM1/exportin1 mediates the nuclear export pathway [9]. CRM1
recognizes the leucine-rich nuclear export signal (NES) and nuclear
export occurs under the regulation of Ran protein. NS2 has a
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is recognized by CRM1. Recent studies have also demonstrated the
existence of additional NESs on NS2 [11], M1 [12], and NP [13]. In
addition, other studies, including our own previous research, have
shown that the nuclear export of vRNP is inhibited by leptomycin B
(LMB) [14,15], which is an inhibitor of the NES–CRM1 interaction
[16]. Biochemical analyses have shown that NS2 directly interacts
with M1 [17–19]. Based on these observations, it was hypothesized
that the nuclear export of vRNP is mediated by the vRNP–M1–
NS2–CRM1 complex [20–22]. Thus, NS2 is designated as the
nuclear export protein (NEP). However, other reports suggest that
NS2 is not essential for the nuclear export of vRNP because it does
not colocalize with vRNP [23], and viruses that contained muta-
tions in the NES of NS2 could be recovered [10]. It has been spec-
ulated that NS2 is not essential for the nuclear export of vRNP–M1
complex. Therefore, we explored the new M1-binding factor,
which is related to the nuclear export of vRNP, and found that
the host heat shock cognate protein 70 (Hsc70), a constitutive form
of Hsp70 family protein, can mediate the nuclear export of vRNP
[24]. Hsc70 is involved in the cell entry of rotavirus [25], but little
is known about the role of Hsc70 in the inﬂuenza virus replication
cycle. The LMB-sensitive NES in Hsc70 (394LDVTPLSL401) has been
identiﬁed [26], and it is likely that the nuclear export of vRNP is
regulated by M1, NS2, and Hsc70 [27]. However, the interactions
among M1, NS2, and Hsc70 are not yet well understood.
The present study examined the binding activity of Hsc70 and
inﬂuenza viral NS2 protein with the viral M1 protein based on bio-
chemical analyses. We found that Hsc70 binds to M1 via its pep-
tide-binding domain. Furthermore, we characterized the
dissociation constant (Kd) values of the Hsc70–M1 and NS2–M1
interactions. The interaction of Hsc70–M1 was stronger than that
of NS2–M1, suggesting an important role of Hsc70 in the export
of vRNP.
2. Materials and methods
2.1. Antibodies and vector
The anti-M1 antibody was prepared by a previously described
method [24]. The anti-GST antibody and anti-His antibody were
purchased from GE Healthcare and Santa Cruz, respectively. For
the expression of GST–Hsc70 wild-type (1–646 aa), pGEX2T–
Hsc70 [28] was used. For the expression of GST–fused Hsc70
deletion mutants encoding 1–384 aa (N384), 1–402 aa (N402),
385–646 aa (C385), and 403–646 aa (C403), DNA fragments were
generated by PCR ampliﬁcation (Table 1) from pEGFP–Hsc70
[26]. The resultant PCR fragments were digested with BamHI and
inserted into the BamHI-digested site of pGEX2T. For the expres-
sion of GST–fused Hsc70 deletion mutants encoding 1–462 aa
(N462) and 1–546 aa (N546), Hsc70 cDNA encoding 1–462 aaTable 1
Primers used for the vector construction.
Plasmid Primer Sequences
N384 Hsc70_1aa_F 50-CCGGGATCCATGTCCAAGGGA-30
Hsc70_384aa_R 50-CGGGGATCCCTTGTCTCCAGACAAGATGG-30
N402 Hsc70_1aa_F 50-CCGGGATCCATGTCCAAGGGA-30
Hsc70_402aa_R 50-CGGGGATCCACCAAGGGAAAGAGGAGTG-30
N462 792FH 50-ATGGTCAACCATTTTATTGC-30
1470R 50-CTGTGAGTTCAAACTTGCC-30
N546 F4 50-GGTGTTCCTCAGATTGAAGTC-30
1722R 50-AGGCATAGGACTCAAGTGAA-30
C385 Hsc70_385aa_F 50-CGGGGATCCTCTGAGAATGTTCAAGATTTG
CTG-30
Hsc70_END_R 50-GGTGGATCCGATACTTGGTTG-30
C403 Hsc70_403aa_F 50-CGGGGATCCATTGAAACTGCTGGTGGAG-30
Hsc70_END_R 50-GGTGGATCCGATACTTGGTTG-30and 1–546 aa were generated by PCR ampliﬁcation (Table 1) and
subcloned in-frame into BamHI site of pGEX2T.
2.2. Puriﬁcation of recombinant His–M1, GST–NS2, and GST–Hsc70
His–M1 was puriﬁed in accordance with the pET-system man-
ual (Novagen) and a previous study [17]. In brief, His–M1
expressed by Escherichia coli was sonicated in a binding buffer
[5 mM imidazole, 0.1 M NaCl, 20 mM Tris–HCl (pH 7.9), and 1%
CHAPS], and the puriﬁed His–M1 was immediately used for GST-
pull-down assays. GST–NS2 [17] and GST–Hsc70 [28] were puriﬁed
in accordance with the glutathione Sepharose 4B manual (GE
Healthcare) with some modiﬁcations. In brief, E. coli that expressed
GST-fused protein was sonicated in a NET/NP-40 buffer [50 mM
Tris–HCl (pH 7.9), 0.1 M NaCl, 5 mM EDTA, and 0.1% NP-40], and
the NET/NP-40 buffer was also used as the wash buffer.
2.3. Pull-down assays
For the GST pull-down assay, GST-fused protein bound to 10 ll
(bed volume) of glutathione Sepharose 4B was incubated at 4 C for
1 h with puriﬁed His–M1 in the NET/NP-40 buffer. The beads were
then washed three times with the NET/NP-40 buffer at 4 C. To
detect the GST-fused protein and His–M1, a western blot analysis
was performed using either anti-GST or anti-M1 antibody. For
the His-tag pull-down assay, His–M1 bound to 10 ll (bed volume)
of His-bind resin (Novagen) was incubated for 1 h at 4 C with the
puriﬁed GST-fused protein in the binding buffer. The beads were
then washed three times with the binding buffer at 4 C. Further,
to detect the GST-fused protein and His–M1, a western blot analy-
sis was performed using either anti-GST or anti-His antibody.3. Results
3.1. Hsc70 peptide-binding domain mediates association with M1
To identify the M1 binding region of Hsc70, a far-western blot-
ting assay was performed using Hsc70 deletion mutants (Fig. 1A).
N384 (1–384 aa) contained the ATPase domain, N402 (1–402 aa)
contained the ATPase domain and NES, and N462 contained the
ATPase domain, NES, and the N-terminal half of the peptide-binding
domain. In addition, N546 (1–546 aa) lacked the variable domain,
and C385 (385–646 aa) contained the peptide-binding domain,
NES, and the variable domain but lacked the ATPase
domain. C403 (403–646 aa) contained most of the peptide-binding
domain and the variable domain but lacked the ATPase domain and
NES. The GST-fused deletionmutantswere expressed in E. coli. After
puriﬁcation, we conﬁrmed the quality of the puriﬁed GST-fused
proteins (Fig. 1B). His–M1 was expressed by E. coli and the lysate
was reacted on a PVDF membrane with the puriﬁed GST–Hsc70
mutants. The far-western blotting performed with the GST–Hsc70
wild-type detected strong binding to M1. No signals were detected
without the probe [‘‘()’’] or GST alone. The strongest signal was
detected when the N462 mutant was used as a probe. Only weak
signals were detected with N384 and C403, which lacked the NES
sequence (Fig. 1C). The results shown in Fig. 1C were quantiﬁed
using Image J software (Fig. 1D and Table 2). These results suggest
that the N-terminal half of the peptide-binding domain (385–
462 aa) of Hsc70 is essential for M1 binding.
3.2. C-terminal half of M1 is required for binding to Hsc70
To conﬁrm the Hsc70-binding region of M1, a pull-down assay
was performed using M1 deletion mutants (Fig. 2). M1DN lacked
2–75 aa; M1DM lacked 76–116 aa, including the NLS sequence;
Fig. 1. Association of Hsc70 with M1 via the NES region in the N-terminal half of the peptide-binding domain. (A) Schematic representations of Hsc70 deletion mutants. (B)
Puriﬁed GST-fused Hsc70 deletion mutants. One microgram-equivalent of the puriﬁed GST-fused Hsc70 mutants was loaded onto 10% SDS–PAGE, followed by CBB staining.
(C) Far-western blotting assay. The far-western blotting assay was performed in accordance with a previously reported method [24]. In brief, the crude cell lysate of E. coli that
expressed His–M1 was separated by 10% SDS–PAGE, transferred onto a PVDF membrane, and denatured with 6 M guanidine HCl in TBST for 10 min. After stepwise
renaturating, the membrane was incubated without [‘‘()’’] or with 1 lg/mL of each puriﬁed GST or the series of GST–Hsc70 deletion mutants (see panels A and B). Speciﬁc
signals were detected by western blotting using anti-GST antibody. Representative data from three independent experiments are shown. (D) The band intensity was
measured using ImageJ software. Data represent the means and standard deviations from three independent experiments.
Fig. 2. Association of M1 with Hsc70 via the M1 C-terminal domain. (A) Schematic repres
aa) are indicated. (B) Results of the pull-down assays performed using His-tag-fused M1
resin were incubated with 2.0 lg of GST or GST–NS2. To detect His–M1 and GST–NS2, a w
(upper panel). In this assay, 1/50 of the total volume of His–M1 was loaded as the input (l
10).
Table 2
Relative band intensities for Hsc70–M1 interaction.
Hsc70 mutants Relative band intensities ± SD
GST 0.07 ± 0.05
Wild type 1
N384 0.26 ± 0.19
N402 0.71 ± 0.20
N462 1.09 ± 0.69
N546 0.63 ± 0.10
C385 0.48 ± 0.23
C403 0.23 ± 0.19
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GST–Hsc70 were puriﬁed and used for the in vitro pull-down
assays. GST–Hsc70 was coprecipitated when His-bind resin-immo-
bilized wild-type M1, DN, and DM were used (Fig. 2B: lanes 4, 6,
and 8). No signal was detected when M1DC (lane 8) was used, sug-
gesting that the C-terminal half of M1 is essential for Hsc70
binding.
3.3. Kd values for Hsc70–M1 binding and NS2–M1 binding
We previously reported Hsc70–M1 [24] and NS2–M1 binding
[17] in vitro. In the present study, the binding of Hsc70–M1 andentations of the M1 deletion mutants. The nuclear localization signals (NLS, 101–105
deletion mutants and GST–NS2. The His-tag-fused M1 mutants (1.0 lg) on His-bind
estern blot analysis was performed using either anti-His (lower panel) or anti-GST
anes 1 and 2) and 1/4 of the total volume of each eluted sample was loaded (lanes 3–
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pull-down assays were performed using His–M1 and GST–NS2 or
GST–Hsc70. The unbound and bound fractions were loaded onto
SDS–PAGE, followed by western blotting. Each band was quantiﬁed
and analyzed using ImageJ software. The Kd values for Hsc70–M1
and NS2–M1 binding were 1  107 M and 6  106 M, respec-
tively. These results suggest that the binding of Hsc70–M1 is
stronger than that of NS2–M1.
3.4. Hsc70 competes with NS2 for M1 binding
Next, to elucidate the binding modes of M1, NS2, and Hsc70,
in vitro pull-down assays were performed (Fig. 4). The band inten-
sity of GST–Hsc70 decreased when His–M1 and GST–Hsc70 were
co-incubated with increasing amounts of GST–NS2, whereas that
of GST–NS2 increased (Fig. 4A). Furthermore, the band intensity
of GST–NS2 decreased when His–M1 and GST–NS2 were co-incu-
bated with increasing amounts of GST–Hsc70, whereas that ofFig. 3. Comparison of Hsc70–M1 and NS2–M1 binding. In vitro pull-down assays
were performed using different concentrations of Hsc70 or NS2, as described in
Materials and methods. (A) Saturation kinetics for Hsc70–M1 (closed circle) and
NS2–M1 (open square) binding. (B) Scatchard plot analysis. Hsc70–M1 (closed
circle) and NS2–M1 (open square) are shown.
Fig. 4. Hsc70 competes with NS2 for M1 binding. (A and B) Hsc70 and NS2 compete for M
1), GST–Hsc70 (2.2 lg; lanes 2–5), and increasing amounts of GST–NS2 (2.7, 13.5, and
(2.7 lg; lanes 2–5), and increasing amounts of GST–Hsc70 (2.2, 10.8, and 53.8 lg; lanes 3
the volumes of the eluted pull-down samples were loaded onto SDS–PAGE, followed by d
to NS2. In vitro pull-down assays were performed using GST–Hsc70 (0.5 lg; lanes 3–6) o
lanes 4 and 5, 10 lg; lane 6). In this assay, 1/100 of the total volumes of M1 and NS2 wGST–Hsc70 increased (Fig. 4B). These results suggest that Hsc70
competes with NS2 for M1 binding. To exclude the possibility that
Hsc70 directly binds to NS2, GST pull-down assays were performed
using GST–Hsc70 and His–M1 or His–NS2 (Fig. 4C). As expected,
we conﬁrmed the association between Hsc70 and M1, but no asso-
ciation between Hsc70 and NS2 was detected in our experimental
conditions.
4. Discussion
In this study, we examined the binding of Hsc70 and NS2 to M1
based on biochemical analyses. We found that Hsc70 binds to M1
via its peptide-binding domain and characterized the Kd values of
the Hsc70–M1 and NS2–M1 interactions.
The Scatchard plot analysis showed that the apparent Kd value of
the Hsc70–M1 interaction was 1  107 M (Fig. 3). This is
comparable to other reports for Hsc70-binding proteins. The anti-
cell death protein, BAG-1, binds to Hsc70 as a monomer with a
1:1 stoichiometry (Kd value = 1  107 M) [29]. The interaction
between Hsc70 and 1–20 aa of ribonuclease A has a Kd value of
2.7  106 M [30]. The N-terminal peptide of sickle cell hemoglobin
binds to Hsc70 with a Kd value of 9.3  106 M [30]. It is unlikely
that the ATPase activity of Hsc70 is involved in the Hsc70–M1 inter-
action because the addition of ATP did not affect the Hsc70–M1
binding (data not shown). We also determined the Kd value of the
NS2–M1 interaction (6  106 M). These biochemical experiments
help to elucidate the molecular mechanisms that facilitate the
assembly of viral components. The interaction of Hsc70–M1 was
stronger than that of NS2–M1, thereby suggesting an important
role of Hsc70 in the export of vRNP.
It is well known that the nuclear export of vRNP is suppressed
by LMB, suggesting that vRNP is exported via a CRM1-dependent
pathway. Many studies suggest that M1 and NS2 are crucial for
the nuclear export of vRNP, but the precise mechanism and struc-
ture of the nuclear export vRNP complex still remain controversial.
We previously reported that Hsc70 is associated with vRNP–M11 binding. His–M1 (2 lg) was immobilized on His-bind resin. In panel A, GST (lane
67.3 lg; lanes 3–5) were added to the reaction. In panel B, GST (lane 1), GST–NS2
–5) were added to the reaction. To detect the GST-fused and His–M1 proteins, 1/4 of
etection with anti-GST and anti-His antibodies, respectively. (C) Hsc70 does not bind
n glutathione Sepharose and His–NS2 (2.0 lg; lanes 3, 5, and 6) or His–M1 (2.0 lg;
ere loaded as the input (lanes 1 and 2).
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tains NS2 because Hsc70 did not bind to NS2 directly (Fig. 4C), and
it competed with NS2 for M1 binding (Fig. 4A and B). We detected
no interaction between endogenous Hsc70 and recombinant NS2
when an infected cell lysate was used in the pull-down assay (data
not shown). In addition, it has been reported that the replication of
vRNP is regulated by M1 [31] and NS2 [32,33]. It was recently
reported that NS2 is related to the adaptation of the highly patho-
genic avian virus (H5N1) to a mammalian host [34]. It is likely that
Hsc70 may affect these functions because the localization of Hsc70
drastically changed to the nucleus in the late stages of inﬂuenza
viral infection, where M1 and NS2 were localized in the nucleus
[14]. Hsc70 is constitutively expressed in inﬂuenza virus-suscepti-
ble cell lines, thereby suggesting the important roles of Hsc70 in
inﬂuenza virus replication.
At present, two main classes of anti-inﬂuenza drugs are avail-
able: M2 ion channel inhibitors and NA inhibitors. The use of M2
ion channel inhibitors is limited by the rapid spread of drug-resis-
tant inﬂuenza viruses, their side effects, and their limitation to
inﬂuenza A virus [35]. Resistance to viral NA inhibitors is also
increasing rapidly [36,37]. These factors necessitate the develop-
ment of novel anti-inﬂuenza drugs with less likelihood of resis-
tance emergence. Thus, the regulation of the functions of Hsc70
may lead to the development of new anti-inﬂuenza virus drugs.
In conclusion, we demonstrated the presence of an interaction
domain between M1 and Hsc70. In addition, we determined the
Kd values of the Hsc70–M1 and NS2–M1 interactions. Considering
previous analyses of Hsc70 in the viral life cycle, the regulation of
the M1–NS2 interaction by Hsc70 could potentially be a good tar-
get for the development of anti-inﬂuenza viral drug. Further stud-
ies are ongoing to determine the detailed mechanism of vRNP
export.
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